Xeltis raised €15M in a Series D+ round in Aug 2022. The company is based in Zurich, Switzerland. Investors in the round: Grand Pharmaceutical Group. Data as of 7 Aug 2026.
Reported in EUR — no conversion. €15M
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
